S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Evelo Biosciences News Headlines

$1.77
+0.16 (+9.94%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.62
$1.88
50-Day Range
$1.61
$4.23
52-Week Range
$1.60
$17.13
Volume
208,028 shs
Average Volume
311,060 shs
Market Capitalization
$94.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.75
Get Evelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Evelo Biosciences Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EVLO
News Sentiment

1.75

0.47

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EVLO Articles
This Week

3

1

EVLO Articles
Average Week



Evelo Biosciences (NASDAQ:EVLO) News Headlines Today

SourceHeadline
finance.yahoo.com logoCORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
finance.yahoo.com - May 12 at 3:20 PM
finance.yahoo.com logoEvelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
finance.yahoo.com - May 12 at 10:19 AM
MarketBeat logo-$0.58 EPS Expected for Evelo Biosciences, Inc. (NASDAQ:EVLO) This Quarter
americanbankingnews.com - May 9 at 5:16 AM
MarketBeat logoInvestors Purchase High Volume of Evelo Biosciences Put Options (NASDAQ:EVLO)
americanbankingnews.com - May 6 at 3:09 AM
finance.yahoo.com logoRead Why Did Evelo Discontinue EDP1867 Atopic Dermatitis Program
finance.yahoo.com - April 14 at 3:00 PM
seekingalpha.com logoEvelo stock falls as it puts EDP1867 eczema program on hold
seekingalpha.com - April 14 at 9:59 AM
finance.yahoo.com logoEvelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs
finance.yahoo.com - April 14 at 9:59 AM
fool.com logoEvelo Biosciences, Inc. (EVLO) Q4 2021 Earnings Call Transcript
fool.com - March 24 at 1:39 PM
seekingalpha.com logoEvelo Biosciences GAAP EPS of -$0.54 beats by $0.08
seekingalpha.com - March 24 at 7:56 AM
finance.yahoo.com logoEvelo Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
finance.yahoo.com - March 24 at 7:56 AM
benzinga.com logoEvelo Biosciences's Earnings Outlook
benzinga.com - March 23 at 4:55 PM
benzinga.com logo5EVLO : Evelo Biosciences Q4 2021 Earnings Conference Call On March 2...
benzinga.com - March 18 at 12:40 PM
finance.yahoo.com logoEvelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
finance.yahoo.com - March 17 at 11:11 AM
finance.yahoo.com logoEvelo Biosciences to Host KOL Discussion on Treatment Advances for All Stages of Psoriasis and Potential of SINTAX Medicines
finance.yahoo.com - March 7 at 7:19 AM
finance.yahoo.com logoEvelo Biosciences to Participate in Cowen 42nd Annual Health Care Conference
finance.yahoo.com - March 2 at 7:23 PM
finance.yahoo.com logoWhy Evelo Biosciences (EVLO) Might Surprise This Earnings Season
finance.yahoo.com - March 2 at 7:23 PM
tmcnet.com logoDurable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience's Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis
tmcnet.com - February 28 at 9:24 AM
seekingalpha.com logoEvelo psoriasis therapy EDP1815 shows durable response in phase 2 trial follow up
seekingalpha.com - February 28 at 9:24 AM
finance.yahoo.com logoDurable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis
finance.yahoo.com - February 28 at 9:24 AM
finance.yahoo.com logoAlltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
finance.yahoo.com - February 28 at 9:24 AM
seekingalpha.com logoEvelo Biosciences begins dosing in phase 2 trial of EDP1815 for eczema
seekingalpha.com - February 17 at 10:41 AM
finance.yahoo.com logoEvelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis
finance.yahoo.com - February 17 at 10:41 AM
finance.yahoo.com logoEvelo Biosciences, Inc. (EVLO) Upgraded to Buy: Here's What You Should Know
finance.yahoo.com - February 11 at 3:17 PM
finance.yahoo.com logoEvelo Biosciences' Psoriasis Candidate Shows Reductions In Inflammatory Cytokines
finance.yahoo.com - February 7 at 1:53 PM
seekingalpha.com logoEvelo Biosciences posts biomarker data from Phase 2 psoriasis study
seekingalpha.com - February 7 at 8:53 AM
finance.yahoo.com logoEvelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial
finance.yahoo.com - February 7 at 8:53 AM
finance.yahoo.com logoEvelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases
finance.yahoo.com - January 17 at 9:15 AM
finance.yahoo.com logoEvelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts
finance.yahoo.com - January 4 at 9:40 AM
finance.yahoo.com logoEvelo Biosciences Added to Nasdaq Biotechnology Index
finance.yahoo.com - December 14 at 9:31 AM
finance.yahoo.com logoEvelo Biosciences to Present at 2021 Jefferies London Healthcare Conference
finance.yahoo.com - November 9 at 12:00 PM
finance.yahoo.com logoEvelo Biosciences, Inc. (EVLO) Q3 2021 Earnings Call Transcript
finance.yahoo.com - October 28 at 8:16 PM
finance.yahoo.com logoEvelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights
finance.yahoo.com - October 28 at 10:15 AM
finance.yahoo.com logoEvelo Biosciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
finance.yahoo.com - October 21 at 7:47 AM
nasdaq.com logoHad insiders known Evelo Biosciences, Inc. (NASDAQ:EVLO) would hit US$425m they might have invested more last year
nasdaq.com - October 18 at 10:38 AM
finance.yahoo.com logoHow Many Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares Do Institutions Own?
finance.yahoo.com - October 18 at 10:38 AM
finance.yahoo.com logoWall Street Analysts Believe Evelo Biosciences, Inc. (EVLO) Could Rally 164%: Here's is How to Trade
finance.yahoo.com - October 13 at 2:39 PM
finance.yahoo.com logoEvelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
finance.yahoo.com - October 13 at 8:49 AM
marketwatch.com logoEvelo Biosciences Reports Positive Phase 2 Study of EDP1815 in Psoriasis >EVLO
marketwatch.com - September 28 at 6:18 AM
finance.yahoo.com logoEvelo Biosciences Psoriasis Candidate Shows Benefit In Mid-Stage Study
finance.yahoo.com - September 27 at 12:49 PM
finance.yahoo.com logoEvelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease
finance.yahoo.com - September 27 at 7:48 AM
finance.yahoo.com logoEvelo Biosciences to Present at 2021 Cantor Global Healthcare Conference
finance.yahoo.com - September 20 at 7:57 AM
finance.yahoo.com logoEvelo Biosciences Announces Issuance of U.S. Patent for Pharmaceutical Compositions of Single Strains of Naturally Occurring Bacteria as Medicines
finance.yahoo.com - September 9 at 3:22 PM
finance.yahoo.com logoImplied Volatility Surging for Evelo Biosciences (EVLO) Stock Options
finance.yahoo.com - September 8 at 3:53 PM
finance.yahoo.com logoEvelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors
finance.yahoo.com - September 7 at 7:28 AM
fool.com logoEvelo Biosciences, Inc.(EVLO)
fool.com - August 7 at 7:49 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Evelo (EVLO) Stock?
finance.yahoo.com - August 6 at 1:35 PM
finance.yahoo.com logoEvelo Biosciences, Inc. (EVLO) Q2 2021 Earnings Call Transcript
finance.yahoo.com - July 31 at 8:18 AM
finance.yahoo.com logoEvelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights
finance.yahoo.com - July 29 at 8:37 AM
finance.yahoo.com logoEvelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
finance.yahoo.com - July 22 at 9:51 AM
nasdaq.com logoEvelo Biosciences, Inc. Common Stock (EVLO)
nasdaq.com - July 15 at 8:05 PM
Get Evelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.